Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8⁺ T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma

References

• Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery. 2012;152(3):397–402. doi:10.1016/j.surg.2012.05.007
   PubMed Web of Science ®Google Scholar
• Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol. 2013;8(12):1574–1577. doi:10.1097/01.JTO.0000437008.00554.90
   PubMed Web of Science ®Google Scholar
• Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802. doi:10.1200/JCO.2015.62.0674
   PubMed Web of Science ®Google Scholar
• Ung M, Rouquette I, Filleron T, et al. Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung. Clin Lung Cancer. 2016;17(5):391–397. doi:10.1016/j.cllc.2016.03.001
   PubMed Web of Science ®Google Scholar
• Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer. 2009;125(10):2479–2482. doi:10.1002/ijc.24610
   PubMed Web of Science ®Google Scholar
• Leone A, Graziano P, Gasbarra R, et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer. 2011;128(3):732–735. doi:10.1002/ijc.25335
   PubMed Web of Science ®Google Scholar
• Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol. 2009;39(4):267–270. doi:10.1093/jjco/hyn155
   PubMed Web of Science ®Google Scholar
• Yu Y, Zeng D, Ou Q, et al. Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis. JAMA Netw Open. 2019;2(7):e196879. doi:10.1001/jamanetworkopen.2019.6879
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi:10.1016/j.ccell.2020.10.001
   PubMed Web of Science ®Google Scholar
• Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020;12(1):90. doi:10.1186/s13073-020-00787-6
   PubMed Web of Science ®Google Scholar
• Reuss JE, Anagnostou V, Cottrell TR, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020;8(2):e001282. doi:10.1136/jitc-2020-001282
   PubMed Web of Science ®Google Scholar
• Acharya N, Madi A, Zhang H, et al. Endogenous glucocorticoid signaling regulates CD8(+) T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity. 2020;53(3):658–671 e656. doi:10.1016/j.immuni.2020.08.005
   PubMed Web of Science ®Google Scholar
• Sanchez-Magraner L, Miles J, Baker CL, et al. High PD-1/PD-L1 checkpoint interaction infers tumor selection and therapeutic sensitivity to anti-PD-1/PD-L1 treatment. Cancer Res. 2020;80(19):4244–4257. doi:10.1158/0008-5472.CAN-20-1117
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, Phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi:10.1016/S1470-2045(20)30445-9
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Young A, Jacquelot N, et al. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. 2015;75(18):3800–3811. doi:10.1158/0008-5472.CAN-15-1082
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074. doi:10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Wouters MCA, Nelson BH. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin Cancer Res. 2018;24(24):6125–6135. doi:10.1158/1078-0432.CCR-18-1481
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–i890. doi:10.1093/bioinformatics/bty560
   PubMed Web of Science ®Google Scholar
• Li H, Durbin R. Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics. 2009;25(14):1754–1760. doi:10.1093/bioinformatics/btp324
   PubMed Web of Science ®Google Scholar
• McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–1303. doi:10.1101/gr.107524.110
   PubMed Web of Science ®Google Scholar
• Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2020;38(16):e164. doi:10.1093/nar/gkq603
   Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi:10.1038/nature12213
   PubMed Web of Science ®Google Scholar
• Martincorena I, Raine KM, Gerstung M, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171(5):1029–1041 e1021. doi:10.1016/j.cell.2017.09.042
   PubMed Web of Science ®Google Scholar
• Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41–R41. doi:10.1186/gb-2011-12-4-r41
   PubMed Web of Science ®Google Scholar
• Gehring JS, Fischer B, Lawrence M, Huber W. SomaticSignatures. inferring mutational signatures from single-nucleotide variants. Bioinformatics. 2015;31(22):3673–3675. doi:10.1093/bioinformatics/btv408
   PubMed Web of Science ®Google Scholar
• Yu H, Chen Z, Ballman KV, et al. Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma. J Thorac Oncol. 2019;14(1):25–36. doi:10.1016/j.jtho.2018.09.006
   PubMed Web of Science ®Google Scholar
• Bai Y, Chen X, Hou L, et al. PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. Cancer Biol Med. 2018;15(4):434–442. doi:10.20892/j.issn.2095-3941.2018.0223
   PubMed Web of Science ®Google Scholar
• Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer. 2016;55:7–14. doi:10.1016/j.ejca.2015.11.020
   PubMed Web of Science ®Google Scholar
• Schrock AB, Li SD, Frampton GM, et al. Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling. J Thorac Oncol. 2017;12(6):932–942. doi:10.1016/j.jtho.2017.03.005
   PubMed Web of Science ®Google Scholar
• Yang Z, Xu J, Li L, et al. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nat Commun. 2020;11(1):4878. doi:10.1038/s41467-020-18702-3
   PubMed Web of Science ®Google Scholar
• Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002;87(6):635–644. doi:10.1038/sj.bjc.6600510
   PubMed Web of Science ®Google Scholar
• Johnstone CN, Castellvi-Bel S, Chang LM, et al. ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene. 2004;336(1):59–71. doi:10.1016/j.gene.2004.01.025
   PubMed Web of Science ®Google Scholar
• Myers KA, Nasioulas S, Boys A, et al. ADGRV1 is implicated in myoclonic epilepsy. Epilepsia. 2018;59(2):381–388. doi:10.1111/epi.13980
   PubMed Web of Science ®Google Scholar
• Jouret G, Poirsier C, Spodenkiewicz M, et al. Genetics of usher syndrome: new insights from a meta-analysis. Otol Neurotol. 2019;40(1):121–129. doi:10.1097/MAO.0000000000002054
   PubMed Web of Science ®Google Scholar
• Zhao J, Bai H, Li X, et al. Glucose-sensitive acetylation of Seryl tRNA synthetase regulates lipid synthesis in breast cancer. Signal Transduct Target Ther. 2021;6(1):303. doi:10.1038/s41392-021-00714-0
   PubMed Web of Science ®Google Scholar
• Somasundaram A, Burns TF. The next generation of immunotherapy: keeping lung cancer in check. J Hematol Oncol. 2017;10(1):87. doi:10.1186/s13045-017-0456-5
   PubMed Web of Science ®Google Scholar
• Liu L, Bai X, Wang J, et al. Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. Clin Cancer Res. 2019;25(24):7413–7423. doi:10.1158/1078-0432.CCR-19-0558
   PubMed Web of Science ®Google Scholar
• Reading JL, Galvez-Cancino F, Swanton C, et al. The function and dysfunction of memory CD8(+) T cells in tumor immunity. Immunol Rev. 2018;283(1):194–212. doi:10.1111/imr.12657
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e551. doi:10.1016/S1470-2045(16)30406-5
   PubMed Web of Science ®Google Scholar